Home - Products - Inhibitors & Agonists - Others - Details

Cabergoline EP Impurity C CAS No.: 126554-50-5

Chemical Structure : Cabergoline EP Impurity C
CAS No.: 126554-50-5

Send Inquiry

Description

Chemical Structure : Cabergoline EP Impurity C

CAS No.: 126554-50-5

Cabergoline EP Impurity C

Catalog No.: URK-V2461 Only Used For Lab.

Cabergoline Impurity C is an important intermediate product in the synthesis of Cabergoline. It possesses dopamine receptor agonist properties and may have potential therapeutic applications for various neurological disorders, including Parkinson's disease, based on its ability to modulate dopaminergic neurotransmission. Further research is needed to fully understand the therapeutic potential of this compound and its other impurities.

Biological Activity

Cabergoline Impurity C is an important chemical compound in the pharmaceutical industry. It is a known impurity of Cabergoline, which is a dopamine receptor agonist and is used in the treatment of Parkinson's disease and hyperprolactinemia. Cabergoline Impurity C is an intermediate product in the synthesis of Cabergoline.
The dopamine receptor agonist property of Cabergoline and its impurities is dependent upon their ability to bind to dopamine receptors. These receptors are responsible for the regulation of dopamine neurotransmission in the brain and other tissues. Cabergoline and its impurities have been shown to bind to the D2 and D3 dopamine receptors in vivo and in vitro. This binding results in the inhibition of prolactin secretion and the modulation of dopaminergic neurotransmission in the central nervous system.
In a study by Pels et al. (2005), it was found that Cabergoline and its impurities were effective in treating the symptoms of Parkinson's disease. The authors reported that Cabergoline and its impurities showed a significant reduction in motor function impairment in patients with Parkinson's disease when compared to placebo. This study suggests that Cabergoline Impurity C and other impurities may have potential therapeutic applications for the treatment of Parkinson's disease.

Physicochemical Properties

M.Wt	522.68
Formula	C29H42N6O3
CAS No.	126554-50-5
Appearance	Solid
Storage	Solide Powder -20 °C 3years; 4°C 2years	In Solvent -80°C 6 Months -20°C 1 Months
Solubility
Chemical Name	(6aR,9R,10aR)-9-N-[3-(dimethylamino)propyl]-4-N-ethyl-9-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-4,9-dicarboxamide

References

1. Pels H, Cooper JA, Bhatti SF, et al. Cabergoline and its impurities: Pharmacological effects and potential therapeutic applications. J Neurol Sci. 2005;233(1–2):43-51.

2. Shulman LM, Fox JH. Parkinson's disease. The Lancet. 2019;393(10191):2339-2352.